An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

NCT00542724 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

462

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: VIAject™
DRUG: Regular Human Insulin

Sponsor

Biodel